The present invention relates to an anti-breast-cancer drug comprising composition that is selected from a group of inhibitors of aryl hydrocarbon receptor (AhR), antagonists of AhR, inhibitors of histone deacetylase 6 (HDAC6), antagonists of HDAC6, inhibitors of cAMP responsive element binding protein 1 (CREB1) and inhibitors of protein kinase A (PKA). The anti-breast-cancer drug of the present invention is sufficient to improving estrogen receptor-negative breast cancers, especially for estrogen receptor-negative breast cancers caused by chemical phthalates.本發明係關於一種抗乳癌藥物包含由芳香烴受體抑制劑、芳香烴受體拮抗劑、組蛋白去乙醯化酶6抑制劑、組蛋白去乙醯化酶6拮抗劑、cAMP反應元件結合蛋白抑制劑及蛋白磷酸化激酶抑制劑所組成的群組,係可以改善雌激素受體陰性型乳癌,特別係由塑化劑所引發的乳癌。1...塑化劑2...芳香烴受體3...環化磷酸腺苷4...蛋白磷酸化激酶A5...cAMP反應元件結合蛋白6...組蛋白去乙醯化酶67...cMyc基因
